Study #2023-0935
A Phase 1, multicenter, open-label study of REM-422, a MYB mRNA degrader, in patients with recurrent or metastatic adenoid cystic carcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
REM-422
Description
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
Study phase:
Phase I
Physician name:
Renata Ferrarotto
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-285-5619
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.